|Assessment process complete
|For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended at the submitted price.
Updated June 2017
Following an update to the rapid review of Glycopyrronium bromide (Sialanar®), a full pharmacoeconomic assessment is not recommended.